Development of a novel peripherally acting alpha2A-adrenergic receptor antagonist for anti-diabetic
Feng Hong,Jingyi Wang,Dongsheng Chen,Qian Wang,Shiyi Gan,Fang Ye,Lihua Chen,Huixia Ren,Tongran Zhang,Yinfang Xie,Xiaoyuan Jing,Ruoxi Wang,Zhibin Xu,Jiayan Ren,Cuihan Shi,Shuhui Jia,Xiaoting Huang,Xiawei Xu,Yunhua Zheng,Jing Lu,Wanhua Lin,Ji Dai,Liping Wang,Liangyi Chen,Cao Tang,Huisheng Liu,Tao Xu,Xin Xie,Xin-an Liu,Yang Du,Fajun Nan,Zuxin Chen
DOI: https://doi.org/10.1101/2024.12.17.628818
2024-12-23
Abstract:Yohimbine, a potent alpha2A-adrenergic receptor (α2AAR) antagonist, was found therapeutic potential for type 2 diabetes through improving insulin release. However, the adverse side effects mediated by its actions in the brain hampered its use. Here, based on molecular docking analysis and structural modification, we have developed a novel peripherally acting yohimbine derivative (CDS479-2). CryoEM data found that yohimbine and CDS479-2 have similar interactions with the structure of α2AAR. Importantly, CDS479-2 shows similar α2AAR antagonist activity as yohimbine, but with very limited access to the brain, and thus avoiding the unwanted central effects such as hypertension and anxiety. Acute administration of CDS479-2 by injection or gavage lowered blood glucose levels and improved glucose tolerance in the high-fat diet-induced obesity (DIO) mice, an animal model for human type 2 diabetes. Remarkably, DIO mice received 2 weeks of daily administration of CDS479-2, but not yohimbine, exhibited sustained normoglycaemia, and increased density of the insulin-producing beta cells, in which important proliferation genes were found upregulated. Moreover, the overall protein expression levels of their pancreas were more similar to that of the healthy chow-fed mice. Thus, CDS479-2 may indicate a new direction for type 2 diabetes treatment. Importantly, the strategy we employed in this study will inspire the optimization for drugs that with both peripheral and central targets.
Pharmacology and Toxicology